BDX$192.12
$192.12
Chart
Performance
Key Stats
AI BDX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyBecton, Dickinson and Company demonstrates strong fundamentals with consistent profitability and a stable financial position. While current valuations are moderate and technicals show mixed signals, its position in the essential healthcare sector provides defensive qualities and long-term appeal.
Thematic
BD operates in the resilient and growing healthcare sector, benefiting from global demand for medical devices, diagnostics, and life sciences solutions. Trends like an aging population, increasing healthcare spending, and advancements in medical technology are tailwinds for the company.
Fundamental
Becton, Dickinson and Company exhibits strong profitability with improving margins and consistent revenue growth. Its financial position is solid, supported by healthy cash flow generation and manageable debt levels.
Technical
The stock price is exhibiting mixed signals. While it is trading above key long-term moving averages, short-term indicators suggest a neutral to slightly bearish bias, indicating potential for consolidation or a mild retracement.
| Factor | Score |
|---|---|
| Healthcare Demand | 85 |
| Life Sciences Growth | 80 |
| Innovation in MedTech | 75 |
| Diversification | 85 |
| Regulatory Landscape | 75 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 75 |
| Growth | 65 |
| Balance Sheet Health | 70 |
| Cash Flow | 85 |
| Dividend Yield | 80 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 70 |
| Volume Confirmation | 65 |
| Support & Resistance | 60 |
| Short-term Moving Averages | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Surprises
The company has exceeded EPS estimates in the last 5 reported quarters, demonstrating consistent operational performance and effective earnings management.
Attractive Forward P/E
The forward Price-to-Earnings (P/E) ratio of 35.51 suggests that the company is trading at a reasonable valuation relative to its projected future earnings, especially considering its industry peers.
Bearish Points (7)
High Price-to-Sales Ratio
The trailing Price-to-Sales (P/S) ratio of 3.3 is relatively high, suggesting that the market values each dollar of sales more than in some historical periods or peer comparisons, potentially indicating overvaluation.
Negative Long-Term Performance
The stock has experienced negative performance over longer periods (6M: -25.38%, 1Y: -21.1%), indicating significant underperformance compared to broader market indices and raising concerns about long-term growth prospects.
Calendar
June 2025
30
Next Dividend Date
August 2025
7
Next Earnings Date
H: $3.50
A: $3.40
L: $3.35
H: 5.50B
A: 5.49B
L: 5.47B
September 2025
8
Ex-Dividend Date
Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Seasonals
Price Target
217.71 USD
The 39 analysts offering 1 year price forecasts for BDX have a max estimate of 320.55 and a min estimate of 172.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Global leader in medical technology, direct competitor across many BDX segments including medical devices, surgical, and diabetes care.
Weight: 90
Large healthcare conglomerate with a significant Medical Devices segment (e.g., Ethicon, DePuy Synthes), offering direct and indirect competition.
Weight: 90
Diversified healthcare company with strong presence in diagnostics, medical devices (e.g., diabetes care, cardiovascular), and nutrition, directly competing in diagnostics and diabetes.
Weight: 88
Highly diversified science and technology innovator with strong positions in diagnostics and life sciences, direct competition in laboratory and diagnostic solutions.